Evidence map›Paper›PMID 26194878›Full record

ArticleCancer medicine2015

Clinical relevance of copy number profiling in oral and oropharyngeal squamous cell carcinoma.

Pauline M W van Kempen, Rob Noorlag, Weibel W Braunius, Cathy B Moelans, Widad Rifi, Suvi Savola, Ronald Koole, Wilko Grolman, Robert J J van Es, Stefan M Willems

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 47 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Matricellular proteins: Potential biomarkers in head and neck cancer.Journal of cell communication and signaling · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Pauline M W van KempenDepartment of Otorhinolaryngology, University Medical Center Utrecht, Utrecht, The Netherlands.
Rob NoorlagDepartment of Oral and Maxillofacial Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
Weibel W BrauniusDepartment of Otorhinolaryngology, University Medical Center Utrecht, Utrecht, The Netherlands.
Cathy B MoelansDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Widad RifiTumor diagnostics, MRC-Holland, Amsterdam, The Netherlands.
Suvi SavolaTumor diagnostics, MRC-Holland, Amsterdam, The Netherlands.
Ronald KooleDepartment of Oral and Maxillofacial Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
Wilko GrolmanDepartment of Otorhinolaryngology, University Medical Center Utrecht, Utrecht, The Netherlands.
Robert J J van EsDepartment of Oral and Maxillofacial Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
Stefan M WillemsDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
University Medical Center Utrecht · NLMRC Holland (Netherlands) · NLUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current conventional treatment modalities in head and neck squamous cell carcinoma (HNSCC) are nonselective and have shown to cause serious side effects. Unraveling the molecular profiles of head and neck cancer may enable promising clinical applications that pave the road for personalized cancer treatment. We examined copy number status in 36 common oncogenes and tumor suppressor genes in a cohort of 191 oropharyngeal squamous cell carcinomas (OPSCC) and 164 oral cavity squamous cell carcinomas (OSCC) using multiplex ligation probe amplification. Copy number status was correlated with human papillomavirus (HPV) status in OPSCC, with occult lymph node status in OSCC and with patient survival. The 11q13 region showed gain or amplifications in 59% of HPV-negative OPSCC, whereas this amplification was almost absent in HPV-positive OPSCC. Additionally, in clinically lymph node-negative OSCC (Stage I-II), gain of the 11q13 region was significantly correlated with occult lymph node metastases with a negative predictive value of 81%. Multivariate survival analysis revealed a significantly decreased disease-free survival in both HPV-negative and HPV-positive OPSCC with a gain of Wnt-induced secreted protein-1. Gain of CCND1 showed to be an independent predictor for worse survival in OSCC. These results show that copy number aberrations, mainly of the 11q13 region, may be important predictors and prognosticators which allow for stratifying patients for personalized treatment of HNSCC.

Indexed as

Chromosome AberrationsDNA Copy Number VariationsAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Squamous CellCCN Intercellular Signaling ProteinsChromosomes, Human, Pair 11Cyclin D1Disease-Free SurvivalFemaleGenes, Tumor SuppressorHuman papillomavirus 16Human Papillomavirus DNA TestsHumansBiomarkers, TumorCCN4 protein, humanCCND1 protein, humanCCN Intercellular Signaling ProteinsCyclin D1Proto-Oncogene Proteins11q13copy number aberrationsHPVlymph node metastasesoral cavity SCCoropharyngeal SCC

Identifiers

PMID26194878
PMCPMC4618623
OpenAlexW1551308263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.